In these initiatives, immune checkpoint blockers like anti-programmed cell death protein 1 (PD-1) and anti-PD-L1 antibodies have demonstrated effectiveness in certain groups of HCC patients by re-energizing the inhibited immune response directed towards the tumor. This evidence concerns the gene CD274 and hepatocellular carcinoma.